The histological significance of atypical glandular cells on cervical cytology: Experience at Groote Schuur Hospital, Cape Town, South Africa

L D Hoffman,1 MSc; H-T Wu,2 MB BCh, MMed, FCPath, FRCPATH

1 MB ChB III candidate, Faculty of Health Sciences, University of Cape Town, South Africa
2 Division of Anatomical Pathology, Department of Pathology, Faculty of Health Sciences, University of Cape Town; South African Medical Research Council Gynaecological Cancer Research Centre, Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town; and D7 Anatomical Pathology Laboratory, Groote Schuur Hospital/National Health Laboratory Service, Cape Town, South Africa

Corresponding author: L D Hoffman (hoffmanld@yahoo.com)

Background. Atypical glandular cells (AGC) identified on Pap tests may be markers for potentially significant pathology.

Objectives. Primarily, to correlate AGC findings at Groote Schuur Hospital (GSH), Cape Town, South Africa, with subsequent histological investigations and attempt to identify predictors of pathology relevant to the clinical management of women with a cytological diagnosis of AGC. Secondly, to compare the GSH data with data from similar international studies.

Methods. Records of AGC Pap tests were retrieved from the laboratory database in the anatomical pathology laboratory at GSH and clinically relevant information was summarised based on the available information. Standard descriptive statistics were used to summarise the study data, and Fisher’s exact test was used to compare categorical outcomes, where possible.

Results. Of the 237 women with a cytological diagnosis of AGC and who had subsequent histological diagnoses, 120 (50.6%) had significant pathology (cervical intraepithelial neoplasia (CIN) 2 or worse). Significant cervical pathology was most common in women aged <50 years, while significant endometrial pathology predominated in women aged ≥50 years. The results of the GSH study were largely consistent with international findings, but the risk of malignancy was six times higher in the GSH population than in a comparable international group.

Conclusion. AGC identified on Pap tests may be markers for potentially significant pathology. Human papillomavirus DNA testing is recommended for younger women diagnosed with AGC to reduce invasive investigations and minimise expenses in a resource-poor setting.


The 2001 Bethesda System for Reporting Cervical Cytology represents the latest international consensus for classifying cervical cytology. In terms of this typology, the finding ‘atypical glandular cells’ (AGC) indicates ‘morphological changes that exceed those normally expected but that are not sufficient to suggest a diagnosis of adenocarcinoma in situ’ (AIS).

AGC is an uncommon cytological interpretation, occurring in <0.5% of routine Pap tests. Given its rarity and the manifold sources of glandular cells, an AGC diagnosis is associated with a high level of interobserver variability and manifold differential diagnoses. However, a cytological diagnosis of AGC is associated with an increased risk of premalignant and invasive lesions. To our knowledge, there have been no studies published in the English language literature correlating AGC classification with histological diagnosis in South African (SA) patients. Our study may therefore be relevant in the SA context, given that cervical carcinoma remains the most common cancer in women in Africa, with an age-standardised mortality rate of 21.0% compared with a worldwide mortality rate of 8.9%. SA is characterised by a high prevalence of HIV infection and low cervical screening rates. Current research estimates that the proportion of HIV-positive patients in Cape Town undergoing at least one Pap test is 13.1%, while <10% of HIV-negative women utilise the available screening programmes.

Objectives

Primarily, to correlate definitive histological findings following a suspicious Pap test diagnosed as AGC and to summarise these findings, given the available data. Secondly, to compare the data from Groote Schuur Hospital (GSH), Cape Town, with similar international studies with the intention of comparing local findings with other published results. Throughout the study, patterns that may improve management of AGC and/or suggest future research, especially in low-resource settings, were sought.

Methods

A retrospective audit of all Pap tests diagnosed as AGC on cervical cytology and subsequent histological investigations performed by the National Health Laboratory Service at GSH was undertaken for the period 17 February 2003 - 31 December 2014. Similar audits as well as studies that explored the clinical significance of AGC were identified using a Medline/PubMed search of the English literature from 1988 to 2015. The search criteria included, but were not limited to, the terms ‘atypical glandular cells’, ‘AGC’, ‘AGUS’, ‘atypical glandular cells and HPV’ and ‘management of atypical glandular cells’.

The total number of patients who received Pap tests over the period 2003 - 2014 was estimated by extracting all Pap test reports from the laboratory information software, Disa*Lab (Laboratory System Technologies, SA) in the anatomical pathology laboratory at GSH and then merging the records with the same identity numbers. Where identity numbers were unavailable, Pap test results that shared hospital number and date of birth were merged to form a single record. Records with no associated histological investigations (167/424) were removed, as were samples deemed insufficient by the pathologist (9/424) and entries with no recorded age (1/424). Recurrent AGC diagnoses over the period of investigation were present (10/424), and
these records were merged and identified accordingly. Following this procedure, there were 237 patients with AGC cytological diagnoses and corresponding histological diagnoses suitable for analysis. In many cases, information regarding HIV status, menopausal classification, postmenopausal bleeding, contraception method, parity, sample adequacy, reason for Pap test, presence of pathogens and condition of the cervix at time of Pap test were selectively recorded. In cases where menopausal status was not indicated, the age of 50 years was considered to be a proxy for menopause. In addition, if patient records indicated postmenopausal bleeding but no menopausal status was provided, these women were inferred to be postmenopausal.

Where histological results relating to the same cytological finding described different pathology in a uterine or extrauterine site at different points in time, these pathologies were recorded in the order of their diagnosis. However, for the purposes of allocating a distinct diagnostic label to each patient, the most clinically significant diagnosis was used. Lesions classified histologically as normal, benign or inflammatory were grouped together. Discrete diagnostic classifications were created for low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), AIS, cervical carcinoma, endometrial hyperplasia (EH), endometrial carcinoma and other (extrauterine) malignancy. Significant pathology was defined to mean a histological diagnosis of CIN2+ (CIN2/3/AIS), EH or carcinoma.

The current protocol at GSH does not include routine testing for human papillomavirus (HPV) genotypes. However, the diagnosis of HSIL and any form of cervical carcinoma strongly suggests infection with high-risk HPV,[10] and where these diagnoses were available they were used as a proxy for infection with high-risk HPV.

The data analysed are included below. Where differences in proportions of categorical variables were computed, Fisher’s exact test was used. Comparisons with a $p$-value of <0.05 were deemed to be statistically significant. Statistical analysis was performed using R version 2.15.3 (R Foundation for Statistical Computing, Austria). Ethics approval was obtained from the Human Research Ethics Committee, University of Cape Town (HREC Ref: 406/2015).

Results

An estimated 410 867 patients received Pap tests over the study period, of which 424 (0.1%) were classified as AGC on cervical cytology. Table 1 sets out the corresponding histological diagnoses recorded for the 237 cases that were suitable for analysis.

Of the 237 women diagnosed with AGC on cervical cytology, 120 (50.6%) were diagnosed with significant clinical disease. Importantly, 76 of the diagnoses in this group (32.1% of the total) were classified as malignancies.

OF AGC diagnoses at GSH, 86 lesions (36.3%) were found to be squamous in origin on histological examination, as opposed to 61 glandular lesions (25.7%).

There was one case of extrauterine pathology (0.4%), namely vaginal malignancy. Seven of the uterine carcinomas (3.0% of the total) were identified histologically as Müllerian mixed tumours.

Data from this study were compared with aggregated data from 24 international studies[10] using similar diagnostic criteria. We summarise this comparison in Table 2.

Age

The mean age of patients in the study was 50.5 years (standard deviation 13.6, median 49.0, range 25 - 91); 120 women (50.6%) were aged <50 years and 117 (49.4%) ≥50 years. The age distribution of women with an AGC diagnosis and subsequent histological correlation at GSH is shown in Fig. 1. A linear trend line was superimposed for endometrial carcinoma ($R^2=0.84$), while polynomial regression was used to fit lines for HSIL ($R^2=0.72$) and cervical carcinoma ($R^2=0.93$).

In the GSH group, the incidence of CIN2+ lesions peaked at age 40 years (mean 41.8), while the prevalence of cervical carcinoma was highest at 49 years (mean 50.1) and that of endometrial carcinoma at 65 years (mean 65.2). An age of ≥50 years was predictive of significant pathology (odds ratio (OR) 2.39, 95% confidence interval (CI) 1.73 - 3.23).

Table 2. Comparison of the histological findings of AGC Pap tests referenced in aggregated international data[10] with data collected at GSH from 2003 to 2014

<table>
<thead>
<tr>
<th>Outcome</th>
<th>International data, % (range)[10]</th>
<th>GSH data, %</th>
<th>Variance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence of AGC</td>
<td>0.3 (0.1 - 6.0)</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>AGC Pap with histology</td>
<td>57.0 (36.3 - 100.0)</td>
<td>56.0</td>
<td>1.0</td>
</tr>
<tr>
<td>AIS</td>
<td>2.9 (0.0 - 15.7)</td>
<td>0.8</td>
<td>2.0</td>
</tr>
<tr>
<td>EH</td>
<td>1.4 (0.0 - 11.8)</td>
<td>0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>Malignancy</td>
<td>5.2 (0.0 - 15.5)</td>
<td>32.1</td>
<td>26.9</td>
</tr>
<tr>
<td>HSIL</td>
<td>11.1 (1.5 - 46.7)</td>
<td>16.9</td>
<td>3.8</td>
</tr>
<tr>
<td>LSIL</td>
<td>8.5 (1.2 - 16.7)</td>
<td>14.8</td>
<td>6.3</td>
</tr>
</tbody>
</table>

Table 1. Histological diagnoses in patients with a cytological diagnosis of AGC

<table>
<thead>
<tr>
<th>Histological diagnosis</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign</td>
<td>82 (36.4)</td>
</tr>
<tr>
<td>LSIL</td>
<td>35 (14.8)</td>
</tr>
<tr>
<td>HSIL (CIN2+)</td>
<td>40 (16.9)</td>
</tr>
<tr>
<td>Cervical AIS</td>
<td>2 (0.8)</td>
</tr>
<tr>
<td>Cervical Ca.</td>
<td>28 (11.8)</td>
</tr>
<tr>
<td>Endometrial Ca.</td>
<td>47 (19.8)</td>
</tr>
<tr>
<td>EH</td>
<td>2 (0.8)</td>
</tr>
<tr>
<td>Vaginal Ca.</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Total</td>
<td>237 (100.0)</td>
</tr>
</tbody>
</table>

Ca. = carcinoma.
Presence of non-HIV/HPV sexually transmitted pathogens. Bacterial infection or the suggested presence of Candida species, Gardnerella vaginalis, herpes simplex virus, Chlamydia or Trichomonas vaginalis was recorded. The prevalence of HSIL or cervical carcinoma was 31.9% in women infected with at least one pathogen v. 29.1% in non-infected women.

Parity. The prevalence of HSIL or cervical carcinoma in multiparous women was 32.3% v. 16.7% in women reported to have borne at most one child.

Contraception. The prevalence of HSIL or cervical carcinoma in multiparous women was 45.9% among women in the GSH group using hormonal contraception v. 38.1% in women using no contraception.

Discussion

In the GSH population of women reported to have AGC on cervical cytology, histological findings confirmed significant pathology in the majority of cases. Women aged ≥50 years were 2.39 times more likely to have significant pathology than women aged <50 years. Other predictive factors were postmenopausal bleeding, recurrent AGC diagnoses, HIV infection, the presence of sexually transmitted pathogens, multiparity, hormonal contraception, absence of the TZ and suspicion of carcinoma on macroscopic assessment of the cervix.

Age is recognised as an important risk factor in the development of significant pathology.[4,10] The GSH data reflect the natural histories of both cervical and endometrial carcinomas, with the latter being nearly 23 times more prevalent in the study population after 50 years of age. Furthermore, the GSH data are aligned with reports suggesting that the development of cervical/endometrial carcinoma takes several years to decades to progress from preneoplastic disease to invasive carcinoma.[4,11] The ratio of squamous to glandular lesions appears consistent with that reported in the literature.[2,4,11]

Postmenopausal bleeding has been shown to predict invasive pathology in women aged >50 years.[12] These findings were confirmed in the GSH population, where women with

Table 3. Histological outcomes in women with a cytological diagnosis of AGC, according to menopausal status and postmenopausal bleeding

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>AGC Dx. (N=237), %</th>
<th>Benign, %</th>
<th>HSIL, %</th>
<th>AIS, %</th>
<th>Cerv Ca., %</th>
<th>Endo Ca., %</th>
<th>Other Dx., %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premenopausal</td>
<td>48.5</td>
<td>18.1</td>
<td>11.8</td>
<td>0.8</td>
<td>5.9</td>
<td>0.0</td>
<td>63.4</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>51.5</td>
<td>32.0</td>
<td>9.8</td>
<td>0.0</td>
<td>11.5</td>
<td>38.5</td>
<td>8.2</td>
</tr>
<tr>
<td>Postmenopausal bleeding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>11.0</td>
<td>46.2</td>
<td>0.0</td>
<td>0.0</td>
<td>3.8</td>
<td>42.3</td>
<td>7.7</td>
</tr>
<tr>
<td>Absent</td>
<td>3.8</td>
<td>11.1</td>
<td>66.7</td>
<td>0.0</td>
<td>11.1</td>
<td>11.1</td>
<td>0.0</td>
</tr>
<tr>
<td>NA</td>
<td>85.2</td>
<td>34.2</td>
<td>16.8</td>
<td>1.0</td>
<td>12.9</td>
<td>17.3</td>
<td>17.8</td>
</tr>
</tbody>
</table>

Dx. = diagnosis; Cerv Ca. = cervical carcinoma; Endo Ca. = endometrial carcinoma; NA = not available.
postmenopausal bleeding were three times more likely to have significant pathology than postmenopausal women who were not experiencing such bleeding.

The prevalence of HIV in SA is estimated to be 12.2% (5.0% in the Western Cape),\[12\] so the incomplete data in respect of HIV status are likely to include several HIV-positive women. Patients with HIV have an increased absolute risk of an AGC diagnosis.\[3\] Furthermore, HIV-positive women are five times more likely to be infected with HPV than HIV-negative women,\[3,9\] which provides a plausible explanation for the higher incidence of squamous cervical lesions in the GSH group.

It is generally agreed that HPV is the agent that causes cervical neoplasia.\[4,9,13\] There are

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>AGC Dx. (N=237), %</th>
<th>Benign, %</th>
<th>HSIL, %</th>
<th>AIS, %</th>
<th>Cerv Ca., %</th>
<th>Endo Ca., %</th>
<th>Other Dx., %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent AGC diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>4.2</td>
<td>30.0</td>
<td>20.0</td>
<td>0.0</td>
<td>20.0</td>
<td>20.0</td>
<td>10.0</td>
</tr>
<tr>
<td>No</td>
<td>95.8</td>
<td>34.8</td>
<td>16.7</td>
<td>0.9</td>
<td>11.5</td>
<td>19.8</td>
<td>16.3</td>
</tr>
<tr>
<td>Cervical condition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy</td>
<td>43.0</td>
<td>43.1</td>
<td>15.7</td>
<td>2.0</td>
<td>7.8</td>
<td>17.6</td>
<td>13.8</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>9.3</td>
<td>36.4</td>
<td>27.3</td>
<td>0.0</td>
<td>18.2</td>
<td>9.1</td>
<td>9.0</td>
</tr>
<tr>
<td>Suspect Ca.</td>
<td>7.6</td>
<td>22.2</td>
<td>0.0</td>
<td>0.0</td>
<td>22.2</td>
<td>50.0</td>
<td>5.6</td>
</tr>
<tr>
<td>NA</td>
<td>40.1</td>
<td>27.4</td>
<td>18.9</td>
<td>0.0</td>
<td>12.6</td>
<td>18.9</td>
<td>22.2</td>
</tr>
<tr>
<td>Adequacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfactory</td>
<td>85.7</td>
<td>36.5</td>
<td>17.2</td>
<td>1.0</td>
<td>11.8</td>
<td>16.7</td>
<td>16.8</td>
</tr>
<tr>
<td>Unsatisfactory</td>
<td>10.1</td>
<td>25.0</td>
<td>16.7</td>
<td>0.0</td>
<td>16.7</td>
<td>37.5</td>
<td>4.1</td>
</tr>
<tr>
<td>NA</td>
<td>4.2</td>
<td>20.0</td>
<td>10.0</td>
<td>0.0</td>
<td>0.0</td>
<td>40.0</td>
<td>30.0</td>
</tr>
<tr>
<td>TZ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>92.8</td>
<td>35.9</td>
<td>17.3</td>
<td>0.9</td>
<td>11.8</td>
<td>17.3</td>
<td>16.8</td>
</tr>
<tr>
<td>Absent</td>
<td>5.5</td>
<td>7.7</td>
<td>15.4</td>
<td>0.0</td>
<td>15.4</td>
<td>61.5</td>
<td>0.0</td>
</tr>
<tr>
<td>NA</td>
<td>1.7</td>
<td>50.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>25.0</td>
<td>25.0</td>
</tr>
<tr>
<td>Reason for Pap test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening</td>
<td>31.6</td>
<td>32.0</td>
<td>26.7</td>
<td>2.7</td>
<td>10.7</td>
<td>10.7</td>
<td>17.2</td>
</tr>
<tr>
<td>Diagnostic</td>
<td>26.2</td>
<td>43.5</td>
<td>6.5</td>
<td>0.0</td>
<td>11.3</td>
<td>25.8</td>
<td>12.9</td>
</tr>
<tr>
<td>NA</td>
<td>42.2</td>
<td>31.0</td>
<td>16.0</td>
<td>0.0</td>
<td>13.0</td>
<td>23.0</td>
<td>17.0</td>
</tr>
<tr>
<td>HIV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>6.8</td>
<td>31.2</td>
<td>43.8</td>
<td>6.2</td>
<td>18.8</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Negative</td>
<td>22.4</td>
<td>45.3</td>
<td>13.2</td>
<td>0.0</td>
<td>5.7</td>
<td>24.5</td>
<td>11.3</td>
</tr>
<tr>
<td>NA</td>
<td>70.9</td>
<td>31.5</td>
<td>15.5</td>
<td>0.6</td>
<td>13.1</td>
<td>20.2</td>
<td>19.1</td>
</tr>
<tr>
<td>Non-HIV/HPV pathogens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>29.1</td>
<td>33.3</td>
<td>29.0</td>
<td>0.0</td>
<td>2.9</td>
<td>10.1</td>
<td>24.7</td>
</tr>
<tr>
<td>Absent</td>
<td>67.9</td>
<td>35.4</td>
<td>12.4</td>
<td>1.2</td>
<td>15.5</td>
<td>23.6</td>
<td>11.9</td>
</tr>
<tr>
<td>NA</td>
<td>3.0</td>
<td>28.6</td>
<td>0.0</td>
<td>0.0</td>
<td>14.3</td>
<td>28.6</td>
<td>28.5</td>
</tr>
<tr>
<td>Multiparity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>14.3</td>
<td>38.2</td>
<td>17.6</td>
<td>0.0</td>
<td>14.7</td>
<td>20.6</td>
<td>8.9</td>
</tr>
<tr>
<td>No</td>
<td>2.5</td>
<td>33.3</td>
<td>0.0</td>
<td>0.0</td>
<td>16.7</td>
<td>0.0</td>
<td>50.0</td>
</tr>
<tr>
<td>NA</td>
<td>83.1</td>
<td>34.0</td>
<td>17.3</td>
<td>1.0</td>
<td>11.2</td>
<td>20.3</td>
<td>16.2</td>
</tr>
<tr>
<td>Contraception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condom</td>
<td>0.4</td>
<td>100.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>None</td>
<td>26.6</td>
<td>28.6</td>
<td>17.5</td>
<td>0.0</td>
<td>20.6</td>
<td>23.8</td>
<td>9.5</td>
</tr>
<tr>
<td>Hormonal</td>
<td>10.1</td>
<td>37.5</td>
<td>37.5</td>
<td>4.2</td>
<td>4.2</td>
<td>0.0</td>
<td>16.6</td>
</tr>
<tr>
<td>Tubal ligation</td>
<td>2.5</td>
<td>83.3</td>
<td>16.7</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0</td>
</tr>
<tr>
<td>NA</td>
<td>60.3</td>
<td>34.3</td>
<td>13.3</td>
<td>0.7</td>
<td>9.8</td>
<td>22.4</td>
<td>19.5</td>
</tr>
</tbody>
</table>

Dx. = diagnosis; Cerv Ca. = cervical carcinoma; Endo Ca. = endometrial carcinoma; NA = not available.
over 100 recognised genotypes of HPV, but types 16 and 18 account
for approximately 70% of cases of CIN.[11] Research also suggests
that HPV DNA testing is useful to differentiate between cervical and
dendometrial lesions[4] and that infection with HPV increases a
woman's risk of cervical pathology significantly.[9] Local studies in
women with atypical cervical cytology have estimated the prevalence
of high-risk HPV at 54.3%.[14] The estimated prevalence of high-risk
HPV in the GSH data would therefore be expected to be closer to the
reported local prevalence, and this represents a serious limitation in
the analysis of the GSH data.

The GSH data point to an increased risk of HPV-associated cervical
lesions in women infected with sexually transmitted pathogens. Research
suggests that co-infection with HPV and other sexually
transmitted diseases increases the risk of cervical carcinoma.[9] In the
GSH study, the risk of HSIL or cervical carcinoma in women with an
AGC diagnosis was higher among those who tested positive for
sexually transmitted pathogens.

There was an increased prevalence of HSIL and cervical carcinoma
among multiparous women in the GSH study, which is consistent with
published research.[9]

Continuous use of oral contraceptives for >5 years has been shown
to increase the risk of significant cervical pathology.[9] Women in the
GSH study using hormonal contraception did have an increased
prevalence of such pathology, but any further inference was limited
given that the duration of use of hormonal contraceptives was not
recorded on the database. The explanation for the increase in endometrial carcinoma in women not using contraception is
probably age-related, given that postmenopausal women do not
require contraception.

The study findings suggest that the prevalence of AGC in the GSH
population is within the range described in the international
literature.[8,9] The notably higher proportion of malignancies in the
GSH data is probably a result of current protocol regarding Pap
testing in the public health system, coupled with a high burden of
HIV/HPV infection in SA. Currently the National Department of
Health offers asymptomatic women three free Pap tests at 10-year
intervals from 30 years of age.[8,9] It is clear, however, that most SA
women have never had a Pap test,[9] and this lack of population-based
screening and treatment facilitates long-term HPV infection, which
poses the single largest risk for cervical carcinoma[13] and probably
explains the elevated comparative risk of malignancy encountered
in poor countries,[9] as observed in the GSH data. In low-resource
settings such as SA, where utilisation of Pap tests is low, HPV
genotyping should be considered as a screening method, especially
in younger women, given that absence of high-risk HPV DNA
renders the risk of significant disease negligible for some time.[9,13,14]
This would facilitate longer screening intervals, with an associated
reduction in screening costs and benefits to patients.

Research has shown that the sensitivity of HPV DNA testing is
equivalent to that of cytological screening and that it may be easier to
implement.[17] In this regard, the introduction of point-of-care HPV
DNA testing using the GeneXpert (Cepheid, USA) cartridge-based
system holds some promise. This qualitative real-time polymerase
chain reaction assay tests for 14 high-risk HPV genotypes in about
1 hour and exhibits clinical performance comparable to current batch
HPV DNA testing, which takes several hours to complete.[9] As a
consequence of SA's high prevalence of HIV and a burdened public
health system, the incidence of tuberculosis and HPV is high.[9]

The National Department of Health has embarked on a national
programme for detecting tuberculosis using the GeneXpert MTB/RIF
assay.[18] The infrastructure already in place could be simultaneously
deployed to run GeneXpert HPV assays as a primary screening tool
or an adjunct to cervical cytology.[20] While this proposal merits
further investigation with regard to cost and feasibility, point-of-care
testing would be beneficial in terms of reducing losses to follow-up in
the SA public health sector, where the turnaround time for a Pap test
is currently around 6 weeks.

Conclusion

In the GSH setting, AGC is a rare but important finding, indicating
significant pathology in a majority of cases, with rates of malignancy
higher than those found in comparable international investigations.[9]
The findings of the GSH study suggest that when AGC is diagnosed
in women aged >50 years, colposcopy and endometrial sampling are
indicated. However, in women diagnosed with AGC aged <50 years and who are HIV- and HPV-negative, more conservative
management could be considered in the form of more frequent Pap
tests and/or HPV genotyping rather than immediate colposcopy.

Acknowledgement

The authors are grateful for valuable input from Prof. L Denny, head of the Gynaecological Cancer Research Centre (funded by the South African Medical Research Council).

cervical cytology. JAMA 2002;287(16):1214-2119. DOI:10.1001/jama.287.16.2114
cytology among women with human immunodeficiency virus. Obstet Gynecol 2009;114(5):1065-
1068. DOI:10.1097/OGG.0b013e3181b5ецb6
cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010;115(5):243-248. DOI:10.1097/AOG.0b013e318199a3b
5. Conferm M, de Bonito L, Carra V, et al. Interlaboratory reproducibility of atypical glandular cells of
J.1365-2025.2008.00372.x
6. Duska LR. Can we improve the detection of glandular cervical lesions: The role and limitations of
the Pap smear diagnosis atypical glandular cells (AGC). Gynecol Oncol 2009;114(3):381-382.
DOI:10.1016/j.ygyno.2009.07.048
7. Zhao C, Flome A, Onakase A, Austin BD. Histologic follow-up results in 662 patients with Pap
test findings of atypical glandular cells. Results from a large academic women's hospital laboratory
Gyno.2008.07.044
2004;100(10):2035-2044. DOI:10.1002/1097-0248(20040515)100:10<2035::AID-CNCR1409>3.0.CO;2-
9. Batty P, Robert L, Denny L. Utilisation and outcomes of cervical cancer prevention services among HIV-
S0968-8080(06)00006-9
11. Schnait P, Guile M, O'Sullivan DM, Srovel J. Clinical significance of atypical glandular cells on
cervical cytology. Obstet Gynecol 2006;117(1):701-708. DOI:10.1097/01.AOG.0000204109.24195.68
2004;100(10):2035-2044. DOI:10.1002/1097-0248(20040515)100:10<2035::AID-CNCR1409>3.0.CO;2-
699.
infection and cytological abnormalities in women in Guangdong Province, South Africa. S Afr Med J
2013;103(5):313-317. DOI:10.7196/SAMJ.6514
infection in women aged >50 years, colposcopy and endometrial sampling are
indicated. However, in women diagnosed with AGC aged <50 years and who are HIV- and HPV-negative, more conservative
management could be considered in the form of more frequent Pap
tests and/or HPV genotyping rather than immediate colposcopy.

Accepted 21 June 2016.